- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00178971
Serotonin 1A Agonists and Cognition in Schizophrenia
June 5, 2017 updated by: Herbert Meltzer, Northwestern University
Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with antipsychotic medications.
Patients will be assigned to take active medication (Buspar)or placebo along with their prescribed antipsychotic medication for six weeks.
Patients' memory and problem-solving ability will be tested before and after medication.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with olanzapine or risperidone for at least three months randomized to receive adjunctive treatment with a 5-HT1A agonist (buspirone, 15-30 mg/day)or placebo.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37212
- Psychiatric Hospital at Vanderbilt
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Subjects must meet all of the following criteria to be eligible for participation in the current research study.
- Subjects will be males and females between 18-65 years of age;
- Subjects will have a definite diagnosis by DSM-IV criteria for Schizophrenia or Schizoaffective Disorder;
- The subjects or their legal guardian must sign the informed consent;
- Subjects currently being treated with olanzapine or risperidone for a duration of at least 3 months
Exclusion Criteria:
- Subjects who are pregnant or lactating
- Subjects who have brain damage and/or neurological disorders
- Subjects who have current substance dependence
- Subjects unable to provide informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
buspirone 15-30 mg qd
|
buspirone 15-30 mg qd
|
Placebo Comparator: 2
placebo
|
placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
This study will examine the effect on cognition of the addition of buspirone compared with addition of a sugar pill to patients treated with olanzapine or risperidone
Time Frame: six weeks
|
six weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Herbert Y Meltzer, M.D., Vanderbilt University Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2003
Primary Completion (Actual)
October 1, 2004
Study Completion (Actual)
October 1, 2004
Study Registration Dates
First Submitted
September 12, 2005
First Submitted That Met QC Criteria
September 12, 2005
First Posted (Estimate)
September 15, 2005
Study Record Updates
Last Update Posted (Actual)
June 7, 2017
Last Update Submitted That Met QC Criteria
June 5, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Psychotic Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Serotonin Receptor Agonists
- Anti-Anxiety Agents
- Buspirone
Other Study ID Numbers
- 020724
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
Bradley LegaRecruiting
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on adjunctive treatment with buspirone
-
Brown UniversityButler HospitalCompleted
-
Ostergotland County Council, SwedenRegion Jönköping CountyNot yet recruiting
-
University of Geneva, SwitzerlandCompletedPeri-Implantitis | Implant ComplicationSwitzerland
-
Region ÖstergötlandRecruitingBehavioral Symptoms | Emotional InstabilitySweden
-
Delphinus Medical Technologies, Inc.University of Chicago; Boston Biomedical Associates; Reed Technical Associates...CompletedBreast Cancer Detection | Dense Breast Parenchyma | Benign Breast Findings | Normal Breast Screening | Abnormal Breast ScreeningUnited States
-
Johns Hopkins Bloomberg School of Public HealthJohns Hopkins University; Massachusetts General Hospital; National Institute... and other collaboratorsCompleted
-
Northwell HealthNational Institutes of Health (NIH)WithdrawnBipolar I DisorderUnited States
-
Delphinus Medical Technologies, Inc.University of Chicago; Boston Biomedical AssociatesCompletedBreast Cancer Detection | Dense Breast Parenchyma | Benign Breast Findings | Normal Breast Screening | Abnormal Breast ScreeningUnited States
-
University of Colorado, DenverBristol-Myers SquibbRecruiting
-
University of LjubljanaUniversity Medical Centre LjubljanaCompletedAntimicrobial Photodynamic Therapy in Patients With Periodontal Disease and Type 2 Diabetes MellitusDiabetes Mellitus, Type 2 | Periodontitis | Periodontal Diseases | Periodontal Pocket | Periodontal Attachment Loss | Periodontal Inflammation